Retension Pharmaceuticals, Inc. Form 8-K — Oct 22, 2026
Retension Pharmaceuticals (Nasdaq: RTSN) appointed Robert Wong as Vice President, Chief Accounting Officer, effective November 2, 2026. Wong brings 30 years of experience, most recently as VP of Accounting at The Save Mart Companies, and previously served as Chief Accounting Officer at Cytokinetics (NASDAQ: CYTK) and as Controller and CAO at Genentech. His compensation includes a $360,000 base salary, a 30% target bonus, a $20,000 sign-on bonus, and options to purchase 25,000 shares vesting over four years.
Key figures
- Sign on bonus
- 20000
- Annual base salary
- 360000
- Bonus target percent
- 30
- Stock options granted
- 25000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.